Dr. Chen has an extensive experience in antibody-drug conjugate (ADC) drug discovery and development. Before founding Phrontline Biopharma in January 2022, he is the ADC platform head of Innovent Biologics (Suzhou China) where he helped set up ADC platform from ground up for the company and was responsible for several ADC programs in discovery and moving them to clinical studies. Before that, he has worked about six years in ADC discovery at Regeneron Pharmaceuticals, where he participated in a variety of ADC programs including several bispecific ADC programs, such as REGN5093M114 in phase I/II in clinics. Dr. Chen received a BS degree in Chemistry from Xiamen University (Xiamen, China) and a PhD degree in Biochemistry from Brigham Young University.